Lv0
0 积分 2023-07-07 加入
Outcomes after venetoclax with hypomethylating agents in myelodysplastic syndromes: a systematic review and meta-analysis
1小时前
已完结
Mannuronic Acid in Low-Risk and Intermediate-1-Risk Myelodysplastic Syndromes
4个月前
已完结
A randomized double‐blind placebo‐controlled study with subcutaneous recombinant human erythropoietin in patients with low‐risk myelodysplastic syndromes
5个月前
已完结
A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine
5个月前
已完结
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
6个月前
已完结
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
6个月前
已完结
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
6个月前
已完结
皖公网安备34019202002308
